Dr. Charles is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1230 York Ave
# 64
New York, NY 10065Phone+1 212-327-7068
Summary
- I am an infectious disease-trained physician-scientist with deep translational and clinical experience in hepatology, immunology, infectious diseases, autoimmunity and fibrosis. Broad clinical research experience in early and late stage drug development, including immunopathogenesis basic/translational research, target identification, biomarker identification, Phase 0-4 trials, and FDA registration.
Education & Training
Rockefeller UniversityMSc, Clinical and Translational Investigation, 2008 - 2009
NYU Grossman School of MedicineFellowship, Infectious Disease, 2002 - 2004- NYU Grossman School of MedicineResidency, Internal Medicine, 1999 - 2003
University of Alabama School of MedicineClass of 1999- University of ChicagoBA, Economics, Cum Laude, 1989 - 1993
Certifications & Licensure
NY State Medical License 2001 - 2026
Clinical Trials
- Characterization of Clonal B Cell Populations in HCV Infection Start of enrollment: 2007 Jan 01
- Pilot Study to Assess Gut Mucosal B Cells in Individuals With HCV and HIV Start of enrollment: 2009 Nov 01
Publications & Presentations
PubMed
- 17 citationsChemokine antagonism in chronic hepatitis C virus infectionEdgar D. Charles, Lynn B. Dustin
The Journal of Clinical Investigation. 2011-01-04 - 42 citationsThe FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients wi...Manal F. Abdelmalek, Edgar D. Charles, Arun J. Sanyal, Stephen A. Harrison, Brent A. Neuschwander-Tetri
Contemporary Clinical Trials. 2021-02-28 - 21 citationsInitial functional and economic status of patients with multivessel coronary artery disease randomized in the Bypass Angioplasty Revascularization Investigation (BARI)Mark A. Hlatky, Edgar D. Charles, F Nobrega, K Gelman, Iain M. Johnstone
The American Journal of Cardiology. 1995-03-23
Journal Articles
- The Lancet Child & Adolescent HealthArun Sanyal, Stephen A Harrison, Edgar D Charles, Stephanie Noviello, Manal F Abdelmalek, Eric J Lawitz, Rohit Loomba, The Lancet
Abstracts/Posters
- A Phase 2 Study of BMS-986036 (Pegylated FGF21) for 12 Weeks in Obese Adults with Type 2 Diabetes Mellitus (T2DM) and a High Prevalence of Fatty LiverEdgar D. Charles, Brent A. Neuschwander-Tetri, Yi Luo, Chunyu Kate Wu, Rose Christian, American Association for the Study of Liver Disease, Boston, 11/13/2016
- A Phase 1 Study of BMS-986171 (Pegylated FGF21) in Healthy Obese SubjectsChunyu Kate Wu1, Edgar D. Charles, Anh Bui, Rose Christian, Malaz AbuTarif, American Association for the Study of Liver Disease, Boston, 11/12/2016
- A Phase 1 Study of BMS-986036 (Pegylated FGF21) in Healthy Obese SubjectsEdgar D. Charles, Linda Morrow, Marcus Hompesch, Yi Luo, Chunyu Kate Wu, Rose Christian, American Association for the Study of Liver Disease, Boston, 10/12/2016
- Join now to see all
Press Mentions
Admilparant Affects Biomarkers in Pulmonary FibrosisSeptember 16th, 2024
Grant Support
- The Pathogenesis Of Autoimmunity In Hepatitis C Virus InfectionNational Institute Of Allergy And Infectious Diseases2008–2012
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
